491 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Purchased by Gilliland Jeter Wealth Management LLC

Gilliland Jeter Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 491 shares of the medical research company’s stock, valued at approximately $261,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Golden State Equity Partners bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $346,000. Sonen Capital LLC lifted its holdings in shares of Thermo Fisher Scientific by 9.0% in the fourth quarter. Sonen Capital LLC now owns 1,963 shares of the medical research company’s stock worth $1,042,000 after acquiring an additional 162 shares during the last quarter. Mountain Pacific Investment Advisers Inc. ID lifted its holdings in shares of Thermo Fisher Scientific by 1.5% in the fourth quarter. Mountain Pacific Investment Advisers Inc. ID now owns 41,671 shares of the medical research company’s stock worth $22,118,000 after acquiring an additional 620 shares during the last quarter. Markel Group Inc. lifted its holdings in shares of Thermo Fisher Scientific by 44.1% in the fourth quarter. Markel Group Inc. now owns 19,600 shares of the medical research company’s stock worth $10,403,000 after acquiring an additional 6,000 shares during the last quarter. Finally, K.J. Harrison & Partners Inc bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $2,748,000. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research reports. JPMorgan Chase & Co. increased their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday. Barclays raised their price objective on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Royal Bank of Canada raised their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $606.76.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock valued at $28,513,384 in the last quarter. 0.32% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.3 %

Shares of TMO traded up $1.87 during trading hours on Friday, reaching $573.60. The stock had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The firm has a 50-day simple moving average of $573.60 and a 200 day simple moving average of $529.90. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $218.95 billion, a price-to-earnings ratio of 36.79, a P/E/G ratio of 2.41 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.54 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.